Amphastar Pharmaceuticals Inc
$
20.56
0.29 (1.43%)
| Volume: | 98,912 | Avg Vol (1m): | 174,603 |
| Market Cap $: | 967.68 Mil | Enterprise Value $: | 990.75 Mil |
| P/E (TTM): | 411.20 | P/B: | 3.08 |
| Earnings Power Value | -3.45 |
| Net Current Asset Value | 0.4 |
| Tangible Book | 5.81 |
| Projected FCF | 5.54 |
| Median P/S Value | 20.33 |
| Graham Number | 2.56 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 7/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 1.37 |
Cash-To-Debt ranked
lower than
59.84%
of
859
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
AMPH:
1.37
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 0.97, Med: 1.53, Max: 2.13
Current: 1.37
|
| Equity-to-Asset | 0.62 |
Equity-to-Asset ranked
higher than
62.18%
of
788
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
AMPH:
0.62
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: 0.62, Med: 0.73, Max: 0.77
Current: 0.62
|
| Debt-to-Equity | 0.18 |
Debt-to-Equity ranked
higher than
71.31%
of
596
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
AMPH:
0.18
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: 0.11, Med: 0.15, Max: 0.19
Current: 0.18
|
| Debt-to-EBITDA | 4.63 |
Debt-to-EBITDA ranked
lower than
100.00%
of
495
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
AMPH:
4.63
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: -14.14, Med: 1.24, Max: 10.61
Current: 4.63
|
| Piotroski F-Score | 7 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 4.39 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.18 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC -0.21%
WACC 8.08%
| ||
Profitability & Growth : 3/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -0.61 |
Operating Margin ranked
lower than
72.78%
of
801
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
AMPH:
-0.61
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: -28.29, Med: -2.19, Max: 13.45
Current: -0.61
|
| Net Margin % | 0.74 |
Net Margin ranked
lower than
70.95%
of
802
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
AMPH:
0.74
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: -5.08, Med: 2.69, Max: 8.86
Current: 0.74
|
| ROE % | 0.71 |
ROE ranked
lower than
67.19%
of
832
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
AMPH:
0.71
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: -4.01, Med: 1.1, Max: 15.5
Current: 0.71
|
| ROA % | 0.48 |
ROA ranked
lower than
65.44%
of
871
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
AMPH:
0.48
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -2.94, Med: 0.83, Max: 11.4
Current: 0.48
|
| ROC (Joel Greenblatt) % | -1.75 |
ROC (Joel Greenblatt) ranked
lower than
67.84%
of
855
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
AMPH:
-1.75
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: -8.69, Med: 0.94, Max: 29.15
Current: -1.75
|
| 3-Year Total Revenue Growth Rate | 5.40 |
3-Year Revenue Growth Rate ranked
lower than
71.12%
of
689
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 291.9, Med: 5.8, Min: -100
AMPH:
4.3
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: -42.8, Med: -30.3, Max: 4.3
Current: 4.3
|
| 3-Year Total EBITDA Growth Rate | 20.80 |
3-Year EBITDA Growth Rate ranked
lower than
100.00%
of
704
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
AMPH:
19.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -45.3, Max: 69.1
Current: 19.6
|
| 3-Year EPS w/o NRI Growth Rate | -26.00 |
3-Year EPS w/o NRI Growth Rate ranked
lower than
100.00%
of
663
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
AMPH:
-26
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
|
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: -26
Current: -26
|
» AMPH's 30-Y Financials
Financials (Next Earnings Date: 2019-08-08)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:AMPH
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Drug Manufacturers » Drug Manufacturers - Specialty & Generic   NAICS : 325412   SIC : 2834 |
| Compare | XKRX:041960 SHSE:600993 SZSE:300401 ISX:SIDO SZSE:002219 XKRX:003520 SZSE:300723 TSXV:OGI NAS:RDUS SHSE:603456 TSE:4569 ROCO:6446 HKSE:02552 SZSE:300702 SZSE:002550 XBRU:MITRA SZSE:300110 SHSE:600750 TPE:1707 SZSE:002750 |
| Traded in other countries | 29A.Germany |
| Address | 11570 6th Street, Rancho Cucamonga, CA, USA, 91730 |
| Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable & inhalation products. Its products are used in hospitals or urgent care clinical settings. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 411.20 |
PE Ratio ranked
lower than
100.00%
of
557
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
AMPH:
411.2
Ranked among companies with meaningful PE Ratio only.
|
PE Ratio range over the past 10 years
Min: 38.53, Med: 208.92, Max: 99999999.99
Current: 411.2
|
| PE Ratio without NRI | 411.20 |
PE without NRI ranked
lower than
100.00%
of
556
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
AMPH:
411.2
Ranked among companies with meaningful PE without NRI only.
|
PE without NRI range over the past 10 years
Min: 38.53, Med: 208.92, Max: 99999999.99
Current: 411.2
|
| PB Ratio | 3.08 |
PB Ratio ranked
higher than
52.38%
of
819
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
AMPH:
3.08
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 1.33, Med: 2.41, Max: 3.8
Current: 3.08
|
| PS Ratio | 3.09 |
PS Ratio ranked
lower than
54.06%
of
775
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
AMPH:
3.09
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 0.53, Med: 3.08, Max: 3.95
Current: 3.09
|
| Price-to-Operating-Cash-Flow | 36.83 |
Price-to-Operating-Cash-Flow ranked
lower than
70.41%
of
392
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
AMPH:
36.83
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
|
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 8, Med: 24.97, Max: 62.95
Current: 36.83
|
| EV-to-EBIT | -228.77 |
EV-to-EBIT ranked
lower than
100.00%
of
572
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
AMPH:
-228.77
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: -2976.1, Med: -30.3, Max: 1051.8
Current: -228.77
|
| EV-to-EBITDA | 76.70 |
EV-to-EBITDA ranked
lower than
100.00%
of
597
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
AMPH:
76.7
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: -194.5, Med: 38.1, Max: 2098
Current: 76.7
|
| EV-to-Revenue | 3.13 |
EV-to-Revenue ranked
higher than
51.32%
of
795
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
AMPH:
3.13
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 1.6, Med: 3, Max: 4.1
Current: 3.13
|
| Current Ratio | 2.06 |
Current Ratio ranked
higher than
50.76%
of
855
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
AMPH:
2.06
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 1.94, Med: 2.79, Max: 3.81
Current: 2.06
|
| Quick Ratio | 1.35 |
Quick Ratio ranked
lower than
57.54%
of
855
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
AMPH:
1.35
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 1.24, Med: 1.64, Max: 2.02
Current: 1.35
|
| Days Inventory | 126.41 |
Days Inventory ranked
lower than
63.31%
of
755
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
AMPH:
126.41
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 82.24, Med: 160.31, Max: 181.84
Current: 126.41
|
| Days Sales Outstanding | 63.43 |
Days Sales Outstanding ranked
higher than
68.96%
of
770
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
AMPH:
63.43
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 38.3, Med: 48.23, Max: 65.04
Current: 63.43
|
| Days Payable | 64.13 |
Days Payable ranked
higher than
77.84%
of
758
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
AMPH:
64.13
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 23.3, Med: 48.19, Max: 64.13
Current: 64.13
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -0.90 |
3-Year Share Buyback Rate ranked
higher than
71.10%
of
571
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 100, Med: -5.3, Min: -815
AMPH:
-0.9
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -79.5, Med: -77.4, Max: -0.9
Current: -0.9
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 3.54 |
Price-to-Tangible-Book ranked
higher than
56.07%
of
749
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 972.22, Med: 3.33, Min: 0.05
AMPH:
3.54
Ranked among companies with meaningful Price-to-Tangible-Book only.
|
Price-to-Tangible-Book range over the past 10 years
Min: 1.75, Med: 2.84, Max: 3.63
Current: 3.54
|
| Price-to-Projected-FCF | 3.71 |
Price-to-Intrinsic-Value-Projected-FCF ranked
lower than
100.00%
of
374
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 209, Med: 2.11, Min: 0.05
AMPH:
3.71
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
|
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 2.5, Med: 3.15, Max: 3.81
Current: 3.71
|
| Price-to-Median-PS-Value | 1.01 |
Price-to-Median-PS-Value ranked
lower than
65.81%
of
743
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
AMPH:
1.01
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.2, Med: 0.98, Max: 1.25
Current: 1.01
|
| Price-to-Graham-Number | 8.03 |
Price-to-Graham-Number ranked
lower than
100.00%
of
481
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 36.65, Med: 1.81, Min: 0.02
AMPH:
8.03
Ranked among companies with meaningful Price-to-Graham-Number only.
|
Price-to-Graham-Number range over the past 10 years
Min: 2.43, Med: 5.35, Max: 33.75
Current: 8.03
|
| Earnings Yield (Joel Greenblatt) % | -0.44 |
Earnings Yield (Greenblatt) ranked
lower than
71.63%
of
867
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
AMPH:
-0.44
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: -5.3, Med: -0.9, Max: 3.9
Current: -0.44
|
More Statistics
| Revenue (TTM) (Mil) $ | 316.06 |
| EPS (TTM) $ | 0.05 |
| Beta | 1.06 |
| Volatility % | 41.07 |
| 52-Week Range $ | 15.04 - 25.43 |
| Shares Outstanding (Mil) | 47.07 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 7 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | Y |
| Higher Asset Turnover yoy | Y |